nod1 inhibitor  (MedChemExpress)

Journal: CNS Neuroscience & Therapeutics

Article Title: NOD 1/ RIP 2 Pathway Promotes Glioma Progression Through Microglial M 2 Polarization

doi: 10.1111/cns.70674

Figure Lengend Snippet: Invasion, migration, and proliferation of glioma cells were suppressed by ML130. (A) Representative EdU assay images of two cell lines (scale bar = 50 μm). (B) Statistical results of the EdU assay. (C) Representative plate cloning assay images of two cell lines. (D) Statistical results of the plate cloning assay. (E) Representative wound healing assay images of two cell lines. (F) Statistical results of the wound healing assay. (G) Representative Transwell invasion assay images of two cell lines. (H) Statistical results of the Transwell invasion assay. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Article Snippet: Rats in the Glioma + ML130 and Glioma + ie‐DAP groups received intraperitoneal injections of ML130 (1 mg/kg; MCE) and ie‐DAP (3 mg/kg; MCE) starting on the 7th day after model establishment and continuing every other day [ ] until the 14th day.

Techniques: Migration, EdU Assay, Cloning, Wound Healing Assay, Transwell Invasion Assay

Journal: CNS Neuroscience & Therapeutics

Article Title: NOD 1/ RIP 2 Pathway Promotes Glioma Progression Through Microglial M 2 Polarization

doi: 10.1111/cns.70674

Figure Lengend Snippet: Microglial polarization was regulated through the NOD1/RIP2 pathway, influencing glioma cell behavior. (A) Schematic diagram of C6‐derived CM and C6/BV2‐derived CM collection and treatment. (B) qRT‐PCR results of Arg1 and CD206 in CM cultured BV2 cells pretreated with ML130. (C) qRT‐PCR results of Arg1 and CD206 in CM cultured BV2 cells pretreated with GSK‐583. (D) qRT‐PCR results of Arg1 and CD206 in CM cultured BV2 cells pretreated with ie‐GAP. (E, F) Representative EdU assay images of C6 cells (scale bar = 50 μm). (G, H) Representative wound healing assay images of C6 cells. (I, J) Representative Transwell assay images of C6 cells treated with C6/BV2‐derived CM. (K, L) Statistical results of the EdU assay. (M, N) Statistical results of wound healing assay. (O, P) Statistical results of the Transwell assay. ** p < 0.01 and *** p < 0.001.

Article Snippet: Rats in the Glioma + ML130 and Glioma + ie‐DAP groups received intraperitoneal injections of ML130 (1 mg/kg; MCE) and ie‐DAP (3 mg/kg; MCE) starting on the 7th day after model establishment and continuing every other day [ ] until the 14th day.

Techniques: Derivative Assay, Quantitative RT-PCR, Cell Culture, EdU Assay, Wound Healing Assay, Transwell Assay

Journal: CNS Neuroscience & Therapeutics

Article Title: NOD 1/ RIP 2 Pathway Promotes Glioma Progression Through Microglial M 2 Polarization

doi: 10.1111/cns.70674

Figure Lengend Snippet: ML130 inhibited glioma cell proliferation. (A) T2WI images of glioma rats on Days 7 and 14. (B) Representative IHC images of MMP9 and Ki67 in rat brain tissues of each group (scale bar = 20 μm) ( n = 6). (C) Comparison of glioma growth rates in the Glioma and Glioma + ML130 groups ( n = 3). (D) Comparison of the expression of Ki67 in rat brain tissue of each group ( n = 6). (E) Comparison of the MMP9 expression in rat brain tissues across the three groups ( n = 6). (F) The effects of different concentrations of ML130 ( n = 3). * p < 0.05, *** p < 0.001.

Article Snippet: Rats in the Glioma + ML130 and Glioma + ie‐DAP groups received intraperitoneal injections of ML130 (1 mg/kg; MCE) and ie‐DAP (3 mg/kg; MCE) starting on the 7th day after model establishment and continuing every other day [ ] until the 14th day.

Techniques: Comparison, Expressing

Journal: CNS Neuroscience & Therapeutics

Article Title: NOD 1/ RIP 2 Pathway Promotes Glioma Progression Through Microglial M 2 Polarization

doi: 10.1111/cns.70674

Figure Lengend Snippet: Invasion, migration, and proliferation of glioma cells were suppressed by ML130. (A) Representative EdU assay images of two cell lines (scale bar = 50 μm). (B) Statistical results of the EdU assay. (C) Representative plate cloning assay images of two cell lines. (D) Statistical results of the plate cloning assay. (E) Representative wound healing assay images of two cell lines. (F) Statistical results of the wound healing assay. (G) Representative Transwell invasion assay images of two cell lines. (H) Statistical results of the Transwell invasion assay. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Article Snippet: Rats in the Glioma + ML130 and Glioma + ie‐DAP groups received intraperitoneal injections of ML130 (1 mg/kg; MCE) and ie‐DAP (3 mg/kg; MCE) starting on the 7th day after model establishment and continuing every other day [ ] until the 14th day.

Techniques: Migration, EdU Assay, Cloning, Wound Healing Assay, Transwell Invasion Assay

Journal: CNS Neuroscience & Therapeutics

Article Title: NOD 1/ RIP 2 Pathway Promotes Glioma Progression Through Microglial M 2 Polarization

doi: 10.1111/cns.70674

Figure Lengend Snippet: Microglial polarization was regulated through the NOD1/RIP2 pathway, influencing glioma cell behavior. (A) Schematic diagram of C6‐derived CM and C6/BV2‐derived CM collection and treatment. (B) qRT‐PCR results of Arg1 and CD206 in CM cultured BV2 cells pretreated with ML130. (C) qRT‐PCR results of Arg1 and CD206 in CM cultured BV2 cells pretreated with GSK‐583. (D) qRT‐PCR results of Arg1 and CD206 in CM cultured BV2 cells pretreated with ie‐GAP. (E, F) Representative EdU assay images of C6 cells (scale bar = 50 μm). (G, H) Representative wound healing assay images of C6 cells. (I, J) Representative Transwell assay images of C6 cells treated with C6/BV2‐derived CM. (K, L) Statistical results of the EdU assay. (M, N) Statistical results of wound healing assay. (O, P) Statistical results of the Transwell assay. ** p < 0.01 and *** p < 0.001.

Article Snippet: Rats in the Glioma + ML130 and Glioma + ie‐DAP groups received intraperitoneal injections of ML130 (1 mg/kg; MCE) and ie‐DAP (3 mg/kg; MCE) starting on the 7th day after model establishment and continuing every other day [ ] until the 14th day.

Techniques: Derivative Assay, Quantitative RT-PCR, Cell Culture, EdU Assay, Wound Healing Assay, Transwell Assay

Journal: CNS Neuroscience & Therapeutics

Article Title: NOD 1/ RIP 2 Pathway Promotes Glioma Progression Through Microglial M 2 Polarization

doi: 10.1111/cns.70674

Figure Lengend Snippet: ML130 inhibited glioma cell proliferation. (A) T2WI images of glioma rats on Days 7 and 14. (B) Representative IHC images of MMP9 and Ki67 in rat brain tissues of each group (scale bar = 20 μm) ( n = 6). (C) Comparison of glioma growth rates in the Glioma and Glioma + ML130 groups ( n = 3). (D) Comparison of the expression of Ki67 in rat brain tissue of each group ( n = 6). (E) Comparison of the MMP9 expression in rat brain tissues across the three groups ( n = 6). (F) The effects of different concentrations of ML130 ( n = 3). * p < 0.05, *** p < 0.001.

Article Snippet: Rats in the Glioma + ML130 and Glioma + ie‐DAP groups received intraperitoneal injections of ML130 (1 mg/kg; MCE) and ie‐DAP (3 mg/kg; MCE) starting on the 7th day after model establishment and continuing every other day [ ] until the 14th day.

Techniques: Comparison, Expressing

Journal: Journal of Inflammation Research

Article Title: Development and Verification of Diagnosis Model for Papillary Thyroid Cancer Based on Pyroptosis-Related Genes: A Bioinformatic and in vitro Investigation

doi: 10.2147/JIR.S478989

Figure Lengend Snippet: qRT-PCR Primer Sequences

Article Snippet: The NOD1 inhibitor Nodinitib-1 (ML130, Topscience) was dosed for 24 h and the cells were lysed in protein lysis buffer (Cell lysis buffer for Western and IP) (Beyotime, China) containing the protease inhibitor PMSF.

Techniques:

Journal: Journal of Inflammation Research

Article Title: Development and Verification of Diagnosis Model for Papillary Thyroid Cancer Based on Pyroptosis-Related Genes: A Bioinformatic and in vitro Investigation

doi: 10.2147/JIR.S478989

Figure Lengend Snippet: Validation of clinical specimens at our center. ( A ). Gene expression in our center: reverse transcription-polymerase chain reaction (RT-PCR) to detect the expression of NOD1, PRKACA, GSDMB, CASP6, and CASP9 genes in our samples (n = 87). ( B and C ). Immunofluorescence staining for CD68 and CD47 in the clinical tissue specimens. ( D and E ). Immunohistochemical staining for CD3 and CD8 in the clinical tissue specimens. ( F ). The PSF of high NOD1 expression and low NOD1 expression. ( G ). Immunofluorescence staining for PD-1 and NOD-1 in the clinical tissue specimens. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: The NOD1 inhibitor Nodinitib-1 (ML130, Topscience) was dosed for 24 h and the cells were lysed in protein lysis buffer (Cell lysis buffer for Western and IP) (Beyotime, China) containing the protease inhibitor PMSF.

Techniques: Biomarker Discovery, Gene Expression, Reverse Transcription, Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction, Expressing, Immunofluorescence, Staining, Immunohistochemical staining

Journal: Journal of Inflammation Research

Article Title: Development and Verification of Diagnosis Model for Papillary Thyroid Cancer Based on Pyroptosis-Related Genes: A Bioinformatic and in vitro Investigation

doi: 10.2147/JIR.S478989

Figure Lengend Snippet: A Total of 90 PTC Cases at Our Center: Correlation Between the NOD1 Expression and Clinicopathological Features

Article Snippet: The NOD1 inhibitor Nodinitib-1 (ML130, Topscience) was dosed for 24 h and the cells were lysed in protein lysis buffer (Cell lysis buffer for Western and IP) (Beyotime, China) containing the protease inhibitor PMSF.

Techniques: Expressing

Journal: Journal of Inflammation Research

Article Title: Development and Verification of Diagnosis Model for Papillary Thyroid Cancer Based on Pyroptosis-Related Genes: A Bioinformatic and in vitro Investigation

doi: 10.2147/JIR.S478989

Figure Lengend Snippet: NOD1 inhibitor ML130 showed significant in vitro anti-PTC activity. ( A and B ). q-PCR and Western blot results of high expression of TPC1 in PTC cells. ( C ). Effect of ML130 application on TPC-1 and BCPAP cell viability using CCK8 assay. ( D ). TPC-1 and BCPAP clone formation and scratch assay to detect the effect of ML130 on cell proliferation and migration ability. ( E ). The effect of ML130 on cell proliferation and migration ability. ( F ). Flow assay to detect the effect of ML130 on TPC-1 and BCPAP death. ( G ). Western blot results demonstrated that TPC-1 and BCPAP showed apoptosis and pyroptosis after ML130 application. Data are shown as mean ± SD for n = 3. * p < 0.05, *** p < 0.001.

Article Snippet: The NOD1 inhibitor Nodinitib-1 (ML130, Topscience) was dosed for 24 h and the cells were lysed in protein lysis buffer (Cell lysis buffer for Western and IP) (Beyotime, China) containing the protease inhibitor PMSF.

Techniques: In Vitro, Activity Assay, Western Blot, Expressing, CCK-8 Assay, Wound Healing Assay, Migration